Şunu aradınız:: pompe (İngilizce - Litvanca)

pompe disease
pompe liga

late-onset pompe disease
pompe liga pasireiškusi vėliau

infantile-onset pompe disease
pompe liga, pasireiškusi kūdikystėje

infantile- and late- onset pompe disease
pompe liga, pasireiškusi kūdikystėje ir vėliau

late-onset pompe disease; pivotal clinical trial
pompe liga, pasireiškusi vėliau; pagrindinis klinikinis tyrimas

some of these occurred in patients with late onset pompe disease.
toki reakcij pasireisk vlyvja pompe ligos stadija sergantiems pacientams.

late-onset pompe disease; other clinical trials and analyses
pompe liga, pasireiškusi vėliau; kiti klinikiniai tyrimai ir analizės

myozyme is used to treat patients who have a confirmed diagnosis of pompe disease.
myozyme yra skirtas pacientams su patvirtinta pompe liga gydyti

glycogen provides the body with energy, but in pompe disease the levels can get too high.
glikogenas aprpina organizm energija, taciau jo kiekis sergant pompe liga gali tapti per didelis.

patients with pompe disease do not have enough of an enzyme, alpha-glucosidase.
sia liga sergantys zmons turi nepakankamai alfa -gliukozidazs fermento.

myozyme is only used under the supervision of a doctor who is knowledgeable in the treatment of pompe disease.
myozime yra vartojamas tik gydytojo, turincio zini apie pompe ligos gydym, prieziroje.

myozyme has been studied in two main studies involving a total of 39 babies and infants with pompe disease.
myozyme veiksmingumas tirtas dviejuose pagrindiniuose tyrimuose, kuriuose iš viso dalyvavo 39 pompe liga sergantys kūdikiai ir vaikai.

infantile-onset pompe disease is a serious disease with no authorised treatment in the european union.
kdikystje pasireiskianti pompe liga yra rimta liga, kuriai europos sjungoje nra registruoto gydymo.

myozyme is an artificial enzyme called alglucosidase alfa ­ this can replace the natural enzyme which is lacking in pompe disease.
myozime yra dirbtinis fermentas, vadinamas agliukozidaze alfa ­ jis gali pakeisti natral ferment, kurio sergant pompe liga, trksta

myozyme treatment should be supervised by a physician experienced in the management of patients with pompe disease or other inherited metabolic or neuromuscular diseases.
gydymą myozyme preparatu turi prižiūrėti gydytojas, turintis patirties dirbant su pacientais, sergančiais pompe liga ar kitomis paveldimomis medžiagų apykaitos ar nervų ir raumenų ligomis.

myozyme is designed to replace the human enzyme, alpha-glucosidase, which people with pompe disease are lacking.
myozyme turi pakeisti zmogaus ferment, alfa ­ gliukozidaz, kurio trksta pompe liga sergantiems asmenims.

patients with advanced pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from infusion associated reactions.
pacientams, sergantiems pažengusia pompe liga, gali būti sutrikusi širdies arba kvėpavimo funkcija, todėl su infuzija susijusios reakcijos jiems gali kelti didesnį pavojų.

myozyme was compared with patients with pompe disease who had not received treatment and did not take part in the studies (historical comparison group) .
myozyme poveikis pacientams buvo lyginimas su pompe liga serganciais pacientais, kurie negavo gydymo ir nedalyvavo tyrimuose (istorin lyginamoji grup) .

a limited number of patients with late-onset pompe disease (see section 5.1) have been treated with myzozyme.
5. 1 skyri) , skaicius buvo gydomas myzozyme preparatu.

a non-typical, more slowly progressive form of infantile-onset pompe disease has been described which is characterised by a less severe cardiomyopathy and consequently a more prolonged survival.
aprašoma netipinė, lėčiau progresuojanti pompe ligos, pasireiškusios kūdikystėje, forma, kuri charakterizuojama žymesne kardiomiopatija ir todėl ilgesniu išgyvenamumu.